Study Comparing Topical Tranexamic Acid and Thrombin Spray for Managing Burn Wounds Using Split Thickness Skin Grafts

What this Trial Is About

Researchers are investigating the use of topical tranexamic acid compared to the current standard of care, Thrombin-JMI, for managing burn wounds that require a split thickness skin graft. The study aims to show that tranexamic acid is not less effective than thrombin in reducing hematoma formation at the wound site and may provide a lower-cost alternative. This Phase 4 trial focuses on patients with specific types of burn injuries and skin graft procedures. Participants will be randomly assigned to one of two groups. In the control group, the wound base is treated with a spray of Thrombin-JMI before the skin graft is applied. In the experimental group, tranexamic acid solution is sprayed onto the wound base instead, using a syringe with a spray tip. Both groups undergo the same surgical preparation, skin graft harvesting, and application process. After surgery, patients receive standard postoperative care in a burn unit. During the study, participants will be assessed at several time points 48 to 72 hours, 7 to 10 days, and 14 days after surgery. At these visits, trained staff will check for hematoma occurrence, measure how well the skin graft is adhering, and note if any reoperation is needed. The study also compares the costs of using tranexamic acid versus thrombin during surgery. Overall, the total participation spans from surgery through the 14-day follow-up period with detailed wound evaluations.

Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft